| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
SK-575 targets PARP1, the Poly (ADP-ribose) polymerase 1 enzyme. As a PROTAC, it induces the proteasomal degradation of PARP1 protein rather than simply inhibiting its enzymatic activity.
|
|---|---|
| ln Vitro |
In MDA-MB-436 and Capan-1 cells, SK-575 suppresses cell growth with IC50 values of 19 ± 6 nM and 56 ± 12 nM, respectively[1]. Good PARP1 degradation activity is demonstrated by SK-575 (0-1 μM, 24 h) in cancer cell lines (MDA-MB-436, Capan-1, and SW620 cells)[1]. SK-575 (0-10 μM, 24 h) efficiently and dose-dependently stimulates the production of γH2AX in MDA-MB-436 and Capan-1 cells[1].
SK-575 demonstrates potent PARP1 degradation activity in various cancer cells, including MDA-MB-436 (IC50=1.26 nM), SW620 (IC50=0.509 nM), and Capan-1 (IC50=6.72 nM) cells. It effectively inhibits the growth of cancer cell lines harboring BRCA1/2 mutations. |
| ln Vivo |
In an HR-deficient xenograft model, SK-575 (25 and 50 mg/kg, intraperitoneally once daily for 5 days) dramatically suppressed tumor development as a single drug [1]. SK-575 (intraperitoneally, once day for five days; 25 mg/kg). injection, single) substantially induced PARP1 degradation in SW620 xenograft tissue, with effects lasting longer than 24 hours, and completely exposed tumors for more than 24 hours in a vehicle [1].
In male BALB/c nude mice bearing Capan-1 xenograft tumors, SK-575 (25 mg/kg or 50 mg/kg, intraperitoneal injection, once daily for 5 days) significantly inhibited tumor growth. The treatment was well tolerated with no observed lethality or significant weight loss. |
| Enzyme Assay |
The degradation activity is quantified using immunoassays. Cancer cells are treated with SK-575, and remaining PARP1 protein levels are measured by Western blot. The DC50 (concentration for 50% degradation) is calculated from the dose-response curves.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: MDA-MB-436, Capan-1 and SW620 cells Tested Concentrations: 10000, 1000, 300, 100, 30, 10, 3, 1, 0.3, in a dose-dependent manner[1]. , 0.1, 0.03 and 0.01 nM Incubation Duration: 24 hrs (hours) Experimental Results: demonstrated good PARP1 degradation activity in these cancer cell lines (MDA-MB-436, Capan-1 and SW620 cells) with IC50 values of 1.26, 6.72 and 0.509 respectively nM. Effectively induces γH2AX formation in MDA-MB-436 and Capan-1 cells in a dose-dependent manner. Cells are seeded in multi-well plates and treated with SK-575 across a concentration range (e.g., 0.01 nM to 10 microM) for 24 hours. Cell viability is measured using CellTiter-Glo or MTT assays. For degradation studies, cells are lysed and PARP1 levels are assessed by Western blot. |
| Animal Protocol |
Animal/Disease Models: Male BALB/c nude mice (bearing xenografted Capan- 1 tumor) [1]
Doses: 25 mg/kg, 50 mg/kg Route of Administration: IP, one time/day for 5 days Experimental Results: Inhibition of tumor growth . These doses (25 and 50 mg/kg) of SK-575 were well tolerated, with no mouse deaths or significant weight loss observed during treatment. Animal/Disease Models: Female ICR mice (20-23 g, 6-7 weeks old, n=3 per group) [1] Doses: 25 mg/kg Route of Administration: intraperitoneal (ip) injection, single dose (pharmacokinetic/PK/PK analysis) Experimental Results: pharmacokinetic/PK/PK parameters of SK-575 in female ICR mice[1]. Parameter mean Tmax (h) 0.25 Cmax (ng/mL) 1843 AUCall (ng/mL*h) 5316 AUCinf (ng/mL*h) 5363 t1/2 (ng/mL) 3.08 For in vivo efficacy, cancer cells are implanted subcutaneously into BALB/c nude mice. Once tumors reach a certain volume, mice receive intraperitoneal injections of SK-575 (25 or 50 mg/kg) or vehicle daily for 5 consecutive days. Tumor size and body weight are monitored. |
| ADME/Pharmacokinetics |
Comprehensive PK profiling is limited. As a PROTAC molecule with high molecular weight (876.97 g/mol), SK-575 is typically administered via intraperitoneal injection in preclinical studies rather than oral gavage due to expected poor oral bioavailability.
|
| Toxicity/Toxicokinetics |
Toxicology data primarily from efficacy studies shows that SK-575 is well tolerated at 25 and 50 mg/kg (IP) in mice, with no observed animal lethality or significant weight loss during the treatment period. Extended toxicology studies are not reported.
|
| References | |
| Additional Infomation |
SK-575 represents an advanced approach to PARP1 inhibition, using targeted protein degradation. This mechanism may overcome resistance associated with conventional PARP inhibitors. The compound is in preclinical research stages and not approved for clinical use.
|
| Molecular Formula |
C47H53FN8O8
|
|---|---|
| Molecular Weight |
876.97093462944
|
| Exact Mass |
876.397
|
| CAS # |
2523016-96-6
|
| PubChem CID |
162664494
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
5
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
64
|
| Complexity |
1770
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC(NCCNC(=O)CCCCCCCCCCC(N3CCN(C(C4C(=CC=C(CC5=NNC(=O)C6=CC=CC=C56)C=4)F)=O)CC3)=O)=C12
|
| InChi Key |
HPBWDZVXFSTVMR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C47H53FN8O8/c48-35-19-18-30(29-37-31-12-9-10-13-32(31)43(60)53-52-37)28-34(35)45(62)55-26-24-54(25-27-55)41(59)17-8-6-4-2-1-3-5-7-16-39(57)50-23-22-49-36-15-11-14-33-42(36)47(64)56(46(33)63)38-20-21-40(58)51-44(38)61/h9-15,18-19,28,38,49H,1-8,16-17,20-27,29H2,(H,50,57)(H,53,60)(H,51,58,61)
|
| Chemical Name |
N-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethyl]-12-[4-[2-fluoro-5-[(4-oxo-3H-phthalazin-1-yl)methyl]benzoyl]piperazin-1-yl]-12-oxododecanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~114.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1403 mL | 5.7014 mL | 11.4029 mL | |
| 5 mM | 0.2281 mL | 1.1403 mL | 2.2806 mL | |
| 10 mM | 0.1140 mL | 0.5701 mL | 1.1403 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
